Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Status: active

This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.

Inclusion Criteria

Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
Able to take oral medication
If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements
Adequate organ function and electrolytes Key

Exclusion Criteria

Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812
Impaired cardiac function
Major surgery within 28 days of the first dose of study drug

Have a question?
We're here to help

Chat with us: LiveHelp
Call us: 1-800-4-CANCER
(1-800-422-6237)

Which trials are right for you?

Use the checklist in our guide to gather the information you’ll need.

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Description

Eligibility Criteria

Locations & Contacts

Trial Objectives and Outline

Trial Phase & Type

Lead Organization

Trial IDs

Have a question?We're here to help

Which trials are right for you?

Have a question?
We're here to help